Skip to content

Tolvaptan versus Water therapy in Autosomal Dominant Polycystic Kidney Disease

Tolvaptan versus Water therapy in Autosomal Dominant Polycystic Kidney Disease: A pilot randomised controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/045945
Enrollment
64
Registered
2022-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N288- Other specified disorders of kidney and ureter

Interventions

Intervention1: High water therapy: water intake to achieve target serum osmolality Control Intervention1: Tolvaptan: Tolvaptan will be started doses of 30 mg and 15 mg in morning and evening respectiv

Sponsors

Post Graduate Institute of Medical Education and Research Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients with estimated glomerular filtration rate � 60 mL/min/1.73 m2 and TKV � 750ml as measured on CT 2) Patients with estimated GFR of 25 to 60 ml/minute/1.73 m2 3) ADPKD Mayo class 1C, 1D, 1E (as per study definitions given below) with estimated GFR of > 25ml/minute/1.73 m2

Exclusion criteria

Exclusion criteria: 1) Imaging suggestive of atypical ADPKD as per mayo classification (as per study definitions given below). 2) Liver disease other than presence of cystic liver disease consistent with ADPKD 3) Elevation of liver enzymes in the pre randomization period with serum transaminases to � 3 times the upper limit of the normal range, elevations in the total bilirubin to � 2 times the upper limit of the normal range. 4) Patients requiring diuretic therapy 5) Patients with severe cardiopulmonary disease preventing high water intake. 6) Subjects with diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Primary outcomes: Change in total kidney volume (TKV) at one year in Tolvaptan and high water intake therapy groups. Timepoint: 1 year

Secondary

MeasureTime frame
1) Genetic analysis of patients in the two groups 2) Change in estimated glomerular filtration rate (based on MDRD creatinine equation ) 3) Comparison of average urine osmolality, copeptin levels through one year follow up in the two groups. 4) Comparison of adverse effects of the treatment regime in the two groups.Timepoint: 1 year

Countries

India

Contacts

Public ContactDR SMITA DIVYAVEER

Post Graduate Institute of Medical Education and Research, Chandigarh.

divyaveer.ss@gmail.com01722756731

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026